Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olamkicept (TJ301) in active ulcerative colitis
NCT03235752Phase 2Completed
- Sponsor
- I-Mab
- Start
- Feb 2018
- Primary completion
- Dec 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 3
01
Overview
A Phase 2 trial of olamkicept in ulcerative colitis (UC), sponsored by I-Mab. Started Feb 2018; status: completed.
02
Drugs
olamkicept
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03235752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03235752.